Benzinga | May 4, 2021 06:49AM EDT

Sage Therapeutics Q1 EPS $(1.64) Beats $(1.91) Estimate, Sales $1.58M Miss $2.00M Estimate

Sage Therapeutics (NASDAQ:SAGE) reported quarterly losses of $(1.64) per share which beat the analyst consensus estimate of $(1.91) by 14.14 percent. This is a 32.79 percent increase over losses of $(2.44) per share from the same period last year. The company reported quarterly sales of $1.58 million which missed the analyst consensus estimate of $2.00 million by 20.85 percent. This is a 30.75 percent decrease over sales of $2.29 million the same period last year.